Bionik Laboratories (Bionik Laboratories) Change In Working Capital : $1.01 Mil (TTM As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Change In Working Capital?

Bionik Laboratories's change in working capital for the quarter that ended in Mar. 2023 was $0.29 Mil.

Bionik Laboratories's change in working capital for the fiscal year that ended in Mar. 2023 was $1.01 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Bionik Laboratories Change In Working Capital Historical Data

The historical data trend for Bionik Laboratories's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Change In Working Capital Chart

Bionik Laboratories Annual Data

Trend

Dec14

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Working Capital

Get a 7-Day Free Trial

-1.49

-0.57

0.40

0.14

1.01

Bionik Laboratories Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Change In Working Capital	Get a 7-Day Free Trial															-0.02	0.16	0.09	0.48	0.29

Bionik Laboratories Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.01 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Bionik Laboratories Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionik Laboratories (Bionik Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Coolidge Hill Road, Watertown, MA, USA, 02472

Website

https://www.bioniklabs.com

Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.

Executives

Remi Gaston-dreyfus	director, 10 percent owner	46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine	director	7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve	director, officer: Chairman	18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves	officer: Executive Vice President & CFO	80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass	officer: See Remarks	34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin	director
Audrey Thevenon	director	4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone	director
Russo Richard Paul Jr	officer: Chief Financial Officer	20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti	officer: Chief Commercial Officer	10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy	officer: Chief Commercialization Office	C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux	director	1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried	officer: VP - U.S. Operations	C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs	officer: Chief Science Officer	C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu	director	716 BROOKS AVENUE, VENICE CA 90291